Across TCGA pan-cancer cohorts, RPS19BP1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPS19BP1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RPS19BP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS19BP1 expression acts as an unfavorable survival marker.

SKCM and LIHC are the cancer types where RPS19BP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.063	0.757	<.001	18	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPS19BP1 tumor-vs-normal RNA expression · all RPS19BP1 data types